Literature DB >> 15009093

Receptor for advanced glycation end-products is a marker of type I lung alveolar cells.

Madoka Shirasawa1, Naoyuki Fujiwara, Susumu Hirabayashi, Hideki Ohno, Junko Iida, Koshi Makita, Yutaka Hata.   

Abstract

Lung alveolar epithelial cells are comprised of type I (ATI) and type II (ATII) cells. ATI cells are polarized, although they have very flat morphology. The identification of marker proteins for apical and basolateral membranes of ATI cells is important to investigate into the differentiation of ATI cells. In this paper, we characterized receptor for advanced glycation end-products (RAGE) as a marker for ATI cells. RAGE was localized on basolateral membranes of ATI cells in the immunoelectron microscopy and its expression was enhanced in a parallel manner to the differentiation of ATI cells in vivo and in primary cultures of ATII cells. RAGE and T1 alpha, a well-known ATI marker protein, were targeted to basolateral and apical membranes, respectively, when expressed in polarized Madine Darby canine kidney cells. Moreover, RAGE was expressed in ATI cells after T1 alpha in vivo and in ex in vivo organ cultures. In conclusion, RAGE is a marker for basolateral membranes of well-differentiated ATI cells. ATI cells require some signal provided by the in vivo environment to express RAGE.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15009093     DOI: 10.1111/j.1356-9597.2004.00712.x

Source DB:  PubMed          Journal:  Genes Cells        ISSN: 1356-9597            Impact factor:   1.891


  94 in total

1.  A new rat type I-like alveolar epithelial cell line R3/1: bleomycin effects on caveolin expression.

Authors:  Roland Koslowski; Kathrin Barth; Antje Augstein; Thomas Tschernig; Gerhard Bargsten; Michaela Aufderheide; Michael Kasper
Journal:  Histochem Cell Biol       Date:  2004-06-08       Impact factor: 4.304

2.  Type I alveolar epithelial phenotype in primary culture.

Authors:  Shaohua Wang; Rolf D Hubmayr
Journal:  Am J Respir Cell Mol Biol       Date:  2010-07-08       Impact factor: 6.914

3.  Acute lung injury and alveolar epithelial function.

Authors:  Tokujiro Uchida
Journal:  J Anesth       Date:  2010-12-14       Impact factor: 2.078

Review 4.  The receptor for advanced glycation end products and acute lung injury/acute respiratory distress syndrome.

Authors:  Weidun Alan Guo; Paul R Knight; Krishnan Raghavendran
Journal:  Intensive Care Med       Date:  2012-07-10       Impact factor: 17.440

5.  Plasma levels of soluble receptor for advanced glycation end products in patients with acute respiratory distress syndrome.

Authors:  Weili Gu; Zhihua Xu; Feng Qi; Zhihui Sang; Chunhua Wang; Feng Li
Journal:  Int J Clin Exp Med       Date:  2014-12-15

6.  Pharmacokinetics and lung distribution of a humanized anti-RAGE antibody in wild-type and RAGE-/- mice.

Authors:  Yulia Vugmeyster; David DeFranco; Debra D Pittman; Xin Xu
Journal:  MAbs       Date:  2010-09-01       Impact factor: 5.857

7.  Differentiated human alveolar epithelial cells and reversibility of their phenotype in vitro.

Authors:  Jieru Wang; Karen Edeen; Rizwan Manzer; Yongsheng Chang; Shuanglin Wang; Xueni Chen; C Joel Funk; Gregory P Cosgrove; Xiaohui Fang; Robert J Mason
Journal:  Am J Respir Cell Mol Biol       Date:  2007-01-25       Impact factor: 6.914

8.  Receptor for advanced glycation end products is targeted by FBXO10 for ubiquitination and degradation.

Authors:  John Evankovich; Travis Lear; Alison Mckelvey; Sarah Dunn; James Londino; Yuan Liu; Bill B Chen; Rama K Mallampalli
Journal:  FASEB J       Date:  2017-05-17       Impact factor: 5.191

9.  Plasma receptor for advanced glycation end products and clinical outcomes in acute lung injury.

Authors:  C S Calfee; L B Ware; M D Eisner; P E Parsons; B T Thompson; N Wickersham; M A Matthay
Journal:  Thorax       Date:  2008-06-19       Impact factor: 9.139

10.  Alpha-4/beta-1 and alpha-L/beta-2 integrins mediate cytokine induced lung leukocyte-epithelial adhesion and injury.

Authors:  L A Parmley; N D Elkins; M A Fini; Y-E Liu; J E Repine; R M Wright
Journal:  Br J Pharmacol       Date:  2007-09-10       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.